*ST绿康公告称，公司股票连续3个交易日（2026年1月5 - 7日）收盘价格涨幅偏离值累计12.24%，属异 常波动。2025年前三季度，公司营收40,967.34万元，同比降13.21%；归母净利润-8,258.85万元，同比增 47.39%；扣非归母净利润-9,163.06万元，同比增48.13%。截至2025年9月30日，归母所有者权 益-10,638.20万元，仍为负，同比降305.00%。若2025年度经审计期末净资产为负，公司将被终止上市。 ...

证券时报·数据宝统计，截至发稿，中瓷电子收盘价为78.24元，上涨6.62%，本期筹码集中以来股价累 计上涨8.91%。具体到各交易日，4次上涨，4次下跌，其中，涨停1次。 中瓷电子12月22日披露，截至12月20日公司股东户数为25549户，较上期（12月10日）减少5696户，环 比降幅为18.23%。 融资融券数据显示，该股最新（12月19日）两融余额为4.77亿元，其中，融资余额为4.70亿元，本期筹 码集中以来融资余额合计减少4448.67万元，降幅为8.65%。 公司发布的三季报数据显示，前三季公司共实现营业收入21.43亿元，同比增长13.62%，实现净利润 4.43亿元，同比增长20.07%，基本每股收益为0.9800元，加权平均净资产收益率7.15%。（数据宝） （文章来源：证券时报网） ...

交易所数据显示，12月12日，富瑞特装收盘9.55元，上涨4.37%，滚动市盈率PE（当前股价与前四季度 每股收益总和的比值）达到21.46倍，创919天以来新低，总市值57.05亿元。 张家港富瑞特种装备股份有限公司的主营业务是天然气液化和LNG储存、运输、终端应用全产业链装 备制造及提供一站式整体技术解决方案及运维服务、重型装备制造。公司的主要产品是液化工厂装置、 LNG/L-CNG加气站设备、低温液体运输车、低温液体罐式集装箱、LNG储罐、车（船）用LNG供气系 统、速必达、系列低温阀门；各类化工及海工等方面的塔器、换热器、反应器等压力容器及LNG船 罐；LNG加工运维服务及销售相关业务等。报告期内，富瑞深冷荣获江苏省机械行业协会颁发的"江苏 省机械行业创新型先进企业"荣誉称号，富瑞新能获评为"2025年度苏州市创新型中小企业"，长隆装备 被评为"中石化优秀承包商"。 最新一期业绩显示，2025年三季报，公司实现营业收入23.63亿元，同比减少7.90%；净利润1.73亿元， 同比增加36.93%，销售毛利率23.07%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13富瑞特装21.4626 ...

刘强东：我跟兄弟们说，一年净利润低于一百亿，就不要跟我谈这叫利润 刘强东：我跟兄弟们说， 一年净利润低于一百亿，就不要跟我谈这叫利润 刘强东：我跟兄弟们说，一年净利润低于一百亿，就不要跟我谈这叫利润。 特别声明：以上文章内容仅代表作者本人观点，不代表新浪网观点或立场。如有关于作品内容、版权或其它问 题请于作品发表后的30日内与新浪网联系。 ...

Core Insights - Mingde Biological's stock closed at 18.85 yuan on November 24, with a PE ratio of 617.61 and a total market capitalization of 4.383 billion yuan [1] - The average PE ratio in the medical device industry is 52.19, with a median of 40.14, placing Mingde Biological at the 122nd position in the industry ranking [1] - As of the Q3 2025 report, six institutions hold shares in Mingde Biological, with a total of 11.8782 million shares valued at 226 million yuan [1] Company Overview - Mingde Biological specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments [1] - The company's main products include in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] - The company received the "Outstanding Award" at the 2022 Guanggu Quality Awards in February 2023, recognizing its high-quality development [1] - In February 2024, the company was awarded the "8th Wuhan Mayor Quality Award" by the Wuhan Municipal Government [1] Financial Performance - For Q3 2025, Mingde Biological reported revenue of 227 million yuan, a year-on-year increase of 0.53% [1] - The net profit for the same period was 13.5155 million yuan, reflecting a year-on-year decrease of 83.30% [1] - The sales gross margin stood at 32.31% [1] Industry Comparison - Mingde Biological's PE ratio of 617.61 significantly exceeds the industry average of 52.19 and the median of 40.14 [2] - The company ranks last among its peers in terms of PE ratio, with the next highest being Jiuan Medical at 10.21 [2] - The industry average market capitalization is 109.78 billion yuan, while Mingde Biological's market cap is 4.383 billion yuan [2]

Financial Data and Key Metrics Changes - The company reported a recurring EBITDA of BRL 1.5 billion, reflecting a decrease of approximately 16.3% compared to the previous year [10] - The recurring net profit saw a significant drop of around 30.2%, influenced by increased depreciation from major investments and higher interest rates [12] - The company confirmed a triple-A rating from Moody's, indicating strong resilience in its financial position [4] Business Line Data and Key Metrics Changes - Distribution results were negatively impacted by large clients migrating to the basic network, affecting overall performance [4] - In the generation segment, the company faced challenges due to lower GSF (Generation Scaling Factor), necessitating energy purchases that resulted in a BRL 54 million impact [11] - The trading business experienced a reduction in margins, leading to a BRL 136 million impact on distribution [11] Market Data and Key Metrics Changes - The energy market experienced a drop of 4.4%, affecting all segments including rural, commercial, and industrial [18] - The company reported strong collection performance, particularly through digital channels and the PIX instant payment method [19] Company Strategy and Development Direction - The company is maintaining its largest investment program, with BRL 4.7 billion allocated for the quarter, focusing on distribution and substations [5][8] - Investments in regulated areas are expected to yield positive results in the future, particularly in tariff reviews [6] - The company aims to enhance service efficiency by insourcing employees and improving technology [15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in the quarter but emphasized the company's resilience and commitment to its investment plan [4][8] - The CEO highlighted the importance of cautious investments and the favorable position in the trading business for future growth [6] Other Important Information - The company received recognition as the best energy company in Brazil by Vision Negócios and other awards for financial performance and sustainability [21] - The healthcare plan for retired employees was approved, contributing to the company's sustainability efforts [5] Q&A Session Summary Question: Inquiry about technical note 53 and its impact on loss reporting - The management clarified that the new method for calculating losses does not retroactively affect past calculations and that they remain within regulatory limits [24][25] Question: Question regarding trading strategy and energy balance changes - The Chief Trading Officer explained that the company is focused on closing positions rather than opening new ones, influenced by market conditions [26][27]

Core Viewpoint - The company expects to achieve a net profit of no more than RMB 50 million for the six months ending September 30, 2025, compared to a net loss of approximately RMB 26.2 million in the same period last year [1] Group 1 - The increase in profit is primarily attributed to a reduction in valuation losses from investment properties during the period [1] - The company anticipates a decrease in impairment losses on financial assets and contract assets for the period [1]

Financial Performance - China Life's Q3 2025 revenue and net profit attributable to shareholders increased by 54.8% and 91.5% year-on-year, reaching 298.7 billion and 126.9 billion respectively, driving year-to-date revenue and net profit growth to 25.9% and 60.5% [1] - The company's net assets attributable to shareholders grew by 22.8% year-to-date to 625.8 billion by the end of Q3, outperforming peers whose growth ranged from -2.5% to 16.9% [1] - The total investment return rate increased by 104 basis points year-on-year to 6.42% [1] Business Development - New policy sales showed a significant improvement, with new premium growth accelerating from -4.5% in Q1 2025 to 10.4% in Q1-3 2025, and Q3 alone saw a strong growth of 52.5% [2] - The new business value (NBV) growth rate also improved, rising from 4.8% in Q1 2025 to 41.8% in Q1-3 2025, attributed to a strong individual insurance sales team and effective marketing strategies [2] Investment Performance - Total investment income for the first three quarters of 2025 increased by 41% to 368.6 billion, with a total investment return rate of 6.42% [2] - The company likely benefited from an increase in equity investments and capitalized on the growth stock market in Q3 2025 [2] Profit Forecast - The company forecasts net profits for 2025-2027 to be 173.5 billion, 153.8 billion, and 186.4 billion respectively, with year-on-year growth rates of 62%, -11.4%, and 21.2% [3] - The estimated embedded value per share for 2025-2027 is projected to be 57.1, 60.2, and 65.3 yuan, with current price-to-embedded value (PEV) ratios of 0.75, 0.71, and 0.66 [3]

Investment Rating - Industry Rating: Recommended [4] Core Insights - The report indicates that Agnico Eagle's gold production in Q3 2025 increased by 0.1% quarter-on-quarter to 26.96 tons, with a year-on-year increase of 0.4% [1] - The average gold price in Q3 2025 was $3,476 per ounce, reflecting a year-on-year increase of 39.5% and a quarter-on-quarter increase of 5.7% [1] - The company's revenue for Q3 2025 reached $3.06 billion, representing a year-on-year growth of 41.9% and a quarter-on-quarter growth of 8.7% [3] Production and Operational Performance - Gold production for Q3 2025 was 866,936 ounces (26.96 tons), with contributions from LaRonde, Malartic, and Macassa mines, offset by declines in Fosterville and Meliadine mines [1] - The unit production cost for gold in Q3 2025 was $963 per ounce, up 6.1% year-on-year and 5.7% quarter-on-quarter [2] - The total cash cost per ounce was $994, reflecting a year-on-year increase of 7.9% and a quarter-on-quarter increase of 6.5% [2] Financial Performance - The net income for Q3 2025 was $1.055 billion, showing an 86.1% increase year-on-year but a 1.3% decrease quarter-on-quarter [6] - Adjusted net income for the same period was $1.085 billion, up 89.4% year-on-year and 11.2% quarter-on-quarter [7] - Adjusted EBITDA for Q3 2025 was $2.098 billion, representing a year-on-year increase of 66.9% and a quarter-on-quarter increase of 9.6% [8] Cash Flow and Capital Expenditures - Cash provided by operating activities in Q3 2025 was $1.816 billion, a 67.4% increase year-on-year [9] - Free cash flow before changes in non-cash working capital balances was $1.035 billion, up 83.8% year-on-year [10] - Capital expenditures for Q3 2025 totaled $644 million, with capitalized exploration expenditures of $87 million [11] Guidance and Future Outlook - The company expects to meet its 2025 gold production guidance, having achieved approximately 77% of the midpoint target in the first nine months [12] - The total capital expenditures guidance for 2025 remains unchanged, with expectations for cash costs and all-in sustaining costs to approach the upper limits of the guidance range if gold prices remain high [12][17]

Core Viewpoint - China National Petroleum Corporation (CNPC) reported a mixed financial performance for Q3 2025, with a slight increase in revenue but a decrease in net profit, reflecting resilience amid declining oil prices [1] Financial Performance - For the three months ending September 30, CNPC achieved operating revenue of 719.16 billion yuan, a year-on-year increase of 2.3% [1] - The net profit attributable to shareholders was 42.29 billion yuan, a decrease of 3.9% year-on-year [1] - Basic earnings per share stood at 0.23 yuan for the quarter [1] - For the nine months ending September 30, CNPC's operating revenue was 2,169.26 billion yuan, down 3.9% year-on-year [1] - The net profit attributable to shareholders for the nine months was 126.29 billion yuan, a decrease of 4.9% year-on-year [1] - Basic earnings per share for the nine months was 0.69 yuan [1] Analyst Insights - Goldman Sachs noted that CNPC's Q3 EBITDA and net profit fell by 5% and 4% year-on-year, respectively, but showed resilience compared to a 13% decline in Brent crude oil prices [1] - The EBITDA for the period was 3% higher than Goldman Sachs' expectations, driven by strong performance in upstream and natural gas sales [1] - Capital expenditure for the first three quarters reached 65% of Goldman Sachs' full-year forecast, slightly above the historical average of 61% [1] - Cash flow for the same period was 125% of Goldman Sachs' full-year expectation, compared to a historical average of 108% [1] - According to Credit Lyonnais, CNPC's dividend outlook and stability are considered the best among its peers, making it the preferred choice among the "Big Three" oil companies [1]